Satellos Presents Positive Preclinical Efficacy Data for SAT-3247 at the 2024 MDA Clinical & Scientific Conference

Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today positive preclinical data showing SAT-3247 can improve skeletal muscle function in multiple mouse models of muscle degeneration.

The preclinical data presented show the broad potential of SAT-3247 to improve skeletal muscle function as has been demonstrated in three mouse models of muscle degeneration: mdx model of Duchenne muscular dystrophy (DMD), FLExDUX4 model of facioscapulohumeral muscular dystrophy (FSHD), and a muscle injury model in wildtype mice. In all instances, treatment with SAT-3247 over a three-to-four-week period resulted in a statistically significant improvement in muscle force versus animals receiving placebo.

Frank Gleeson, Cofounder and CEO of Satellos, said, “These data bolster our confidence in developing SAT-3247 for the treatment of diseases and conditions, such as DMD and FSHD, that are characterized by muscle damage in the face of inadequate muscle fiber regeneration. We believe the muscle injury data further expand and broaden the potential for SAT-3247 into non-dystrophy disease indications as well as multiple forms of muscle injury or trauma in otherwise healthy individuals. We continue on our development plan to advance SAT-3247 into first-in-human clinical trials mid-year.”

These data are being presented in a poster at the 2024 MDA Clinical & Scientific Conference being held March 3-6 in Orlando. On Wednesday, March 6, at 12:30pm ET, Phil Lambert, Ph.D., Chief Scientific Officer of Satellos will give an oral presentation, entitled, “SAT-3247: An Oral Small Molecule Inhibitor Targeting AAK1, a Critical Effector of Skeletal Muscle Regeneration.”

The presentation and poster are available on the Events & Presentations page located at: https://ir.satellos.com/events-and-presentations/default.aspx.

About SAT-3247

Satellos SAT-3247 is a small molecule designed to inhibit AAK1, a protein kinase member of the Notch pathway. The Company believes AAK1 inhibition, independent of dystrophin, has the capacity to regulate polarity to restore asymmetric muscle stem cell division, generate muscle progenitor cells, and enable muscle regeneration.

About Duchenne Muscular Dystrophy (DMD)

Duchenne muscular dystrophy (DMD) is an inherited disease caused by mutations in the dystrophin gene that no longer allow the dystrophin protein to function properly. Satellos’s unique small molecule therapeutic approach with SAT-3247 is to regulate a dystrophin-independent pathway to restore innate muscle repair and regeneration with the goal of increasing muscle function. Our approach is intended to work as a standalone therapeutic without regard to genetic mutation status and has the potential to complement genetic medicines and other approaches designed to restore dystrophin production.